In diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.
Papachristou, S., Rizzo, M., Papanas, N. (2022). Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 130(10), 636-637 [10.1055/a-1903-1752].
Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?
Rizzo, Manfredi;
2022-10-01
Abstract
In diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.
| File | Dimensione | Formato | |
|---|---|---|---|
|
eced_06-2022-0161-dia.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
2.63 MB
Formato
Adobe PDF
|
2.63 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
